Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FHGV1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,532
Award facts
- Contract value 100% obligated
- $25,532.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a delivery order valued at $25,532.04 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-unit quantity). This delivery order, issued on December 19, 2025, with an ultimate completion date of December 22, 2025, was awarded without set-aside designation under a firm fixed-price contract structure. DMS Pharmaceutical Group operates as the prime contractor with no identified subcontractors on this award.
This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.9 billion ceiling value extending through December 31, 2036. The PPV-G GEN V represents a significant component of the DLA's $30.3 billion pharmaceutical acquisition strategy designed to ensure reliable supply of branded and generic prescription medications, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. The current delivery order exemplifies the operational execution of this strategic sourcing vehicle, fulfilling the recurring pharmaceutical supply needs of federal military medical facilities through DMS Pharmaceutical Group's established distribution capabilities.
Quick answers
Who was awarded contract SPE2DR26FHGV1?
SPE2DR26FHGV1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26FHGV1 worth?
The government has obligated $25,532 on SPE2DR26FHGV1.
Is contract SPE2DR26FHGV1 an order under another contract?
Yes. SPE2DR26FHGV1 is a delivery order under SPE2DR25D9244, an indefinite delivery contract.
Was contract SPE2DR26FHGV1 competed?
The extent of competition for SPE2DR26FHGV1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award